Clinical Collaborations

DermTech’s validated platform technology is being used to support drug discovery and development programs focused on cancers and inflammatory diseases in clinical research trials from Phase 1-3.

Current Indications:

Alopecia Areata

Atopic Dermatitis

B-Cell Lymphoma


Companion & Complimentary Dx

Ewing Sarcoma

Follicular Lymphoma


Hidradenitis Suppurativa


Mantle Cell Lymphoma




T-cell Lymphoma


Using DermTech’s proprietary technology, pharma partners can stratify and select patients based on initial skin gene expression profiles, identify biomarkers of specific diseases and disease subsets, and track and predict drug responses.

Advances in genomic analysis are revolutionizing the practice of medicine, improving patient care, enabling early disease detection, and advancing the treatment of diseases.

Growing List of Indications:

2016 to 2019 capabilities chart

Novel assays, based on state of the art gene expression analyses, are being developed to improve disease detection and diagnosis across therapeutic areas. DermTech’s proprietary technology enables a variety of tests including gene expression, DNA mutation and microbiome analyses. This paradigm shifting platform uses stratum corneum tissue collected non-invasively with our Adhesive Skin Collection Kit.



Michael Howell, PhD

Non-Invasively Stratifying Atopic Dermatitis Patients Based on Inflammatory Genes, Society for Investigational Dermatology 2021

Michael Howell, PhD

Smart Sticker Enabled Precision Dermatology, Dermatology Summit 2021

Michael Howell, PhD

The Drive for Precision and Personalized Dermatology, Dermatology Drug Development Summit 2020

Get In Touch.

Toll Free:
(866) 450-4223